As with T-ALL (described above), LMO2 expression impaired HR in DLBCL and conferred sensitivity to PARP inhibition (with olaparib) as a single agent as well as in combination with genotoxic agents (doxorubicin alone or the R-CHOP regimen) (130). The gene discussed is PARP1; the disease is diffuse large B-cell lymphoma.